If we haven't popped it by lunch, I don't think so. But when something starts running like this a few days in a row, you never know. There should be some healthy profit taking (for those who bought in over the last few days/weeks) but there are a lot of longs who bought in for the pipeline and potential revenue prior to last year's drop who are still waiting to get whole.
The next pop would likely need either huge progress announcements or anticipation/announcement of an acquisition.
as for this being way overvalued based on revenue flow, anybody who has been involved in clinical trials knows just how expensive these sorts of things are. achn does not have anything on the market so are still going off the $200M infusino they got last year. they expect it to get them to significant milestones in development of their current drugs. they're not desperate for funding at the moment, but they're only a couple of years away from that point. either someone picks them up, or they have no problem getting additional funding by issuing another $5M shares at $10 each for another $50M in capital with minimal dilution... they're not in a bad position if you look at the potential revenue based on what Gilead has done and what similar pipelines are being acquired for.
Biotech is rarely rational when it moves big up or down. But it is fun!
News 
Market Data 
Discover 
